Nelivaptan (INN) codenamed SSR-149415 is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008 Sanofi-Aventis announced that further development of this drug had been halted.
This page contains content from the copyrighted Wikipedia article "Nelivaptan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.